Juno Therapeutics (JUNO) Stock Soars After Celgene (CELG) Acquires $1 Billion Stake in Seattle Company
Genentech (RHHBY)'s Ocrelizumab Wows in Late Stages and Eyes $18 Billion MS Market
New Sarepta (SRPT) CEO's Strategy Bears Fruit With NDA Filing
Vertex (VRTX) Poised to Become Profitable Following Expected FDA Approval of Orkambi
Hikma (HIK.L) Rumored to Be Bidding $2.2B for Boehringer Ingelheim's Roxane Laboratories, As Mallinckrodt (MNK), Perrigo (PRGO) Circle
Two Yale University Health Info Groups Sue FDA, Gilead (GILD) for Hep C Drug Trial Data
AstraZeneca PLC (AZN), Eolas Forge $145M+ Pact On Smoking Cessation Plan
EXCLUSIVE: Analysts Weigh In On Controversial Juno Therapeutics (JUNO)/Celgene (CELG) Deal, With Mixed Feelings Abounding
Roche (RHHBY) Investors Urging Company to Dump Diabetes Unit May Have to Wait
Amgen (AMGN) To Lay Off 330 in Colorado as Part of Almost 4,000 Jobs Cuts Overall
AMAG (AMAG) Coughs Up $700 Million for Stem Cell Company
EXCLUSIVE: Knives Are Out for Biotech, As Bears Snag Options for Bubble Burst
Merck & Co. (MRK) Slashes Contractor Positions at Durham Vaccine Manufacturing Plant
Vitae Pharma (VTAE)’ Diabetes Drug Fails Mid-Stage Trial, the Second Drug in Less Than Six Months to Fail
Novartis AG (NVS) Beefs Up Pain Pipeline With $200 Million+ Spinifex Buy
PAREXEL International (PRXL) to Cut 850 Jobs As New Guidance, Pfizer (PFE) Flow Force Restructuring
EXCLUSIVE: Cancer Therapy Benefits Realized Long After FDA Approval, Study Author Tells BioSpace (DHX)
Bristol-Myers Squibb (BMY) to Lay Off 100 in Discovery, Move 200 Workers to New Cambridge R&D Hub
See All News >
//-->